Blueprint Medicines Corp
BPMC129.460USD
0.0000.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
8.36B시가총액
손실P/E TTM
자세한 내용은 Blueprint Medicines Corp 회사
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Blueprint Medicines Corp 정보
종목 코드 BPMC
회사 이름Blueprint Medicines Corp
상장일Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
직원 수649
유형Ordinary Share
회계 연도 종료Apr 30
주소45 Sidney Street
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02139
전화16173747580
웹사이트https://www.blueprintmedicines.com/
종목 코드 BPMC
상장일Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Blueprint Medicines Corp의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
수익 분석
통화: USD마지막 업데이트: Sun, Apr 6
통화: USD마지막 업데이트: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
사업별USD
이름
수익
비율
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
지역별USD
이름
수익
비율
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
사업별
지역별
사업별USD
이름
수익
비율
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
주식 보유 통계
마지막 업데이트: Wed, Aug 13
마지막 업데이트: Wed, Aug 13
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
기타
63.83%
주주
주주
비율
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
기타
63.83%
주주 유형
주주
비율
Sovereign Wealth Fund
1.66%
Individual Investor
0.20%
Investment Advisor
0.15%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.01%
기타
97.91%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
데이터 없음
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
더 보기
ProShares Merger ETF
비율3.21%
AltShares Event-Driven ETF
비율1.43%
ProShares Ultra Nasdaq Biotechnology
비율0.92%
Goldman Sachs Future Health Care Equity ETF
비율0.84%
Hypatia Women CEO ETF
비율0.73%
First Trust Mid Cap Growth AlphaDEX Fund
비율0.58%
iShares Russell 2000 Growth ETF
비율0.54%
WisdomTree BioRevolution Fund
비율0.49%
SoFi Next 500 ETF
비율0.45%
JPMorgan Fundamental Data Science Small Core ETF
비율0.43%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
